Single-Photon Emission Computed Tomography with 99mTс-1-Thio-D-glucose in Evaluation of the Effectiveness and Prediction of the Results of Treatment of Lymphoproliferative Diseases
Authors:   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Chernov V.I. ,   Research Centrum for Oncotheranostics, Tomsk Polytechnic University, Tomsk, Russia, Dudnikova E.A. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Zelchan R.V. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia,   Research Centrum for Oncotheranostics, Tomsk Polytechnic University, Tomsk, Russia, Bragina O.D. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia,   Research Centrum for Oncotheranostics, Tomsk Polytechnic University, Tomsk, Russia, Medvedeva A.A. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Rybina A.N. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Muravleva A.V. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Kravchuk T.L. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia, Goldberg V.E. ,   Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
Published: February 2023

Purpose: Study of 99mTc-1-thio-D-glucose (99mTc-TG) SPECT using fore possibility to assess the effectiveness of therapy and predict the results of lymphomas treatment. Material and methods: We analyzed 99mTc-TG SPECT data of 30 people with malignant lymphomas: before treatment (SPECT1), after two courses (SPECT2) and after completion of chemotherapy (SPECT3). Results: By the results of SPECT2 analyzing, a complete metabolic response after two courses of chemotherapy (SPECT2–) was observed in 15 patients (50 %). In 15 patients, after 2 cycles of chemotherapy, a partial metabolic response (12 people) or no metabolic response (3 people) was established. These patients constituted the SPECT2+ group. After completion of chemotherapy, a complete metabolic response (SPECT3–) was diagnosed in 21 (70 %) patients. This effect was obtained in 15 (100 %) patients with SPECT2– and in 6 patients (40 %) with SPECT2+. Of the 15 patients in the SPECT2+ group, 9 (60 %) patients after completion of chemotherapy were diagnosed with a partial metabolic response (6 people) or metabolic progression (3 people). By two-year follow-up of patients, show that remission was observed in 23 (77 %) patients (complete remission in 15 people, uncertain complete remission in 8 patients). The relapse group consisted of 7 (23 %) cases, while 4 patients had a relapse of the disease, and 3 had progression. In SPECT2+ group, relapse of the disease was observed in 6 (40 %) cases, and remission in 9 (60 %) patients. While in SPECT2– group 1 (7 %) person relapse was diagnosed and 14 (93 %) were in remission (p<0.05). Conclusion: 99mTc-TG SPECT makes it possible to evaluate the results of lymphomas treatment with high efficiency. The presence of a complete metabolic response of the tumor after two courses of therapy indicates a high level of disease-free survival.